12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Company News  |  Deals

BioTime, California Institute for Regenerative Medicine deal

BioTime will provide five research-grade human embryonic stem cell (hESC) lines to the institute. At the institute's request, BioTime...

Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >